When you try not to check in on your stocks very often, life comes at you fast. Sometimes, that's a good thing. Gene editing stocks have been on an absolute tear, at least the three we're holding in our portfolio. Just look at the 30-day returns for the three OGs of gene editing stocks.

Editas (EDIT) +185%Intellia Therapeutics (NTLA) +94% Crispr Therapeutics (CRSP) +55%

The fact that all stocks are rising in unison is very telling. This is not due to some company-specific event, but rather something happening across all gene-editing stocks. When a group of stocks that's not in the same industry classification moves in unison, that's usually a sign of hype (3D printing investors will remember this all too well.) Turns out there are other gene-editing stocks out there we're not holding which can be found in our Guide to Investing in Gene Editing Stocks. Let's see how they've fared over the past 30 days:

Cellectis (CLLS) +42% Calyxt (CLXT) +20% Sangamo Therapeutics (SGMO) +75%

Subscribe or log in to access our premium content including 250+ premium articles, insightful analytic reports on AI investments for retail investors, and our magnum opus: "Quantigence – A Dividend Growth Investing Strategy".



Source link